Olopatadine/mometasone

Last updated

Olopatadine/mometasone
Clinical data
Trade names Ryaltris
Other namesGSP 301
AHFS/Drugs.com Ryaltris
License data
Pregnancy
category
Routes of
administration 		Nasal spray
ATC code
Legal status
Legal status
Identifiers
KEGG

Olopatadine/mometasone, sold under the brand name Ryaltris, is a fixed-dose combination medication for the treatment of allergic rhinitis and rhinoconjunctivitis in adults and adolescents twelve years of age and older. [1] [4] [5] It contains olopatadine hydrochloride and mometasone furoate monohydrate. [1] [4] It is sprayed into the nose. [1] [4]

Common side effects include an unpleasant taste (dysgeusia). [1]

It was approved for medical use in Australia in December 2019, [1] [6] and in the United States in January 2022. [4]

References

  1. 1 2 3 4 5 6 7 "Ryaltris (olopatadine hydrochloride and mometasone furoate monohydrate) Nasal Spray" . Retrieved 25 July 2020.
  2. ↑ "Ryaltris Product information". Health Canada . 17 March 2023. Retrieved 16 February 2025.
  3. ↑ "Details for: Ryaltris". Drug and Health Products Portal. 17 March 2023. Retrieved 16 February 2025.
  4. 1 2 3 4 5 "Ryaltris- olopatadine hydrochloride and mometasone furoate spray, metered". DailyMed. 9 January 2022. Retrieved 20 June 2022.
  5. ↑ Chen R, Zheng D, Zhang Y, Sima G (September 2021). "Efficacy and safety of twice-daily olopatadine-mometasone combination nasal spray (GSP301) in the treatment of allergic rhinitis: a systematic review and meta-analysis". European Archives of Oto-rhino-laryngology. 279 (4): 1691–1699. doi:10.1007/s00405-021-07085-w. PMID   34591150. S2CID   238223252.
  6. ↑ "Ryaltris nasal spray approved in Australia". OINDPnews. 20 December 2019. Retrieved 25 July 2020.


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.